Merck

Covance adds two to clinical development services leadership team

Monday, July 14, 2014 01:04 PM

Covance has announced two key additions to its clinical development services scientific leadership team with the appointments of Robert Wasserman, M.D., as vice president and global therapeutic area head, oncology, and Rogelio Mosqueda-Garcia, M.D., Ph.D., as global vice president, early clinical services within medical and scientific affairs. Both are based in Princeton, N.J.

More... »

WIRB Copernicus Group

Merck's biopharmaceutical division appoints Luciano Rossetti global head of R&D

Monday, July 14, 2014 12:59 PM

Merck's biopharmaceutical division has appointed Luciano Rossetti, M.D., executive vice president and global head of R&D as of July 21.

More... »

CRF Health eCOA webinar series

Mersana Therapeutics, Merck ink $792 million agreement

Wednesday, June 25, 2014 02:08 PM

Mersana Therapeutics and the biopharmaceutical division of Merckhave agreed to collaboratively develop next-generation antibody-drug conjugates (ADCs). ADCs are composed of an antibody linked to cytotoxic drugs, whereby the antibody specifically targets and delivers the cytotoxic drug to cancer cells, which could lead to higher drug levels at the tumor site.

More... »

Bionomics, Merck enter research collaboration

Wednesday, June 25, 2014 01:47 PM

Bionomics has entered into an exclusive research collaboration and license agreement with Merck for its BNC375 research program targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions.  

More... »

Merck to acquire Idenix for $3.85 billion

Monday, June 9, 2014 02:01 PM

Merck has agreed to acquire Idenix Pharmaceuticals for $24.50 per share in cash, for a total value of approximately $3.85 billion. The transaction has been approved by the boards of directors of both companies.

More... »

Merck globally enrolling treatment-naïve adults with HIV-1

Friday, June 6, 2014 01:57 PM

Merck has announced that the first patient has been enrolled in the company’s global phase III clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naïve HIV-1-infected adults. ISENTRESS film-coated tablets currently are administered twice daily in accordance with the approved prescribing Information.

More... »

Dako, Merck to collaborate on companion diagnostic test

Tuesday, June 3, 2014 10:15 AM

Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, is collaborating with Merck to develop a companion diagnostic test for the analysis of the potential tumor biomarker PD-L1 to aid in the treatment of cancer.

More... »

Human Longevity hires for clinical, regulatory/scientific and informatics

Thursday, May 22, 2014 10:43 AM

Human Longevity (HLI), a genomics and cell therapy-based diagnostic and therapeutic company, has announced three senior appointments to help build the company's business and technology platforms.

More... »

Kinex Pharmaceuticals appoints two to New Jersey clinical office

Wednesday, May 14, 2014 03:22 PM

Kinex Pharmaceuticals has announced the addition of two key executives to its clinical leadership team reporting to chief medical officer, Dr. Rudolf Kwan. Douglas Kramer, M.D., joins Kinex as vice president of Clinical and Regulatory Affairs and Jane Devane has joined Kinex as director of Clinical Operations.

More... »

Merck sells ophthalmology business to Santen for $600 million

Wednesday, May 14, 2014 01:33 PM

Santen Pharmaceutical has purchased Merck's ophthalmology products in Japan and key markets in Europe and Asia Pacific.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs